Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension – Pipeline Review, H2 2016, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.
Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 32, 28, 26, 85 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 8 molecules, respectively.
Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
A1M Pharma AB
AbbVie Inc
Actelion Ltd
Afferent Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Anacor Pharmaceuticals Inc
AnGes MG Inc
APT Therapeutics Inc
Arena Pharmaceuticals Inc
Ascendis Pharma A/S
Asklepion Pharmaceuticals LLC
AVEO Pharmaceuticals Inc
Bayer AG
Bial - Portela & Ca SA
Biolab Farmaceutica Ltda
BioRestorative Therapies Inc
Boryung Pharmaceutical Co Ltd
Cellceutix Corp
Celsion Corp
Celtaxsys Inc
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Complexa Inc
Conatus Pharmaceuticals Inc
Corion Biotech Srl
Cumberland Pharmaceuticals Inc
Cytokinetics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Company Ltd
DiaMedica Inc
Eli Lilly and Company
Esperion Therapeutics Inc
F. Hoffmann-La Roche Ltd
Ferring International Center SA
Galectin Therapeutics Inc
Genextra Spa
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenveigh Medical LLC
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
HitGen LTD
Innopharmax Inc
Insmed Inc
INVENT Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
JW Pharmaceutical Corp
Kowa Company Ltd
Leading BioSciences Inc
Lee's Pharmaceutical Holdings Ltd
Les Laboratoires Servier SAS
LFB SA
LG Life Science LTD
LinXis BV
Liquidia Technologies Inc
Lotus Pharmaceutical Co Ltd
MannKind Corp
Mast Therapeutics Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
miRagen Therapeutics Inc
Mitsubishi Tanabe Pharma Corp
Morphogen-IX Ltd
Neurim Pharmaceuticals Ltd
Nippon Kayaku Co Ltd
Nippon Shinyaku Co Ltd
Novartis AG
Noxamet Ltd
Omeros Corp
Peloton Therapeutics Inc
Pfizer Inc
PhaseBio Pharmaceuticals Inc
Pluristem Therapeutics Inc
Polyphor Ltd
Proteo Inc
Pulmokine Inc
Quantum Genomics SA
Reata Pharmaceuticals Inc
RedHill Biopharma Ltd
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
Sanofi
Selten Pharma Inc
Serodus ASA
Shanghai Pharmaceutical Co Ltd
Silence Therapeutics Plc
Simcere Pharmaceutical Group
SteadyMed Therapeutics Inc
Suda Ltd
Sumitomo Dainippon Pharma Co Ltd
Takeda Pharmaceutical Company Ltd
The Medicines Company
Theravance Biopharma Inc
Toray Industries Inc
Torrent Pharmaceuticals Ltd
TSH Biopharm Corporation Ltd
United Therapeutics Corp
VBS Pharmaceuticals
Vectura Group Plc
VG Life Sciences Inc
Vicore Pharma AB
XORTX Pharma Corp
XuanZhu Pharma Co Ltd
Yuhan Corp
'
Table of Contents
Table of Contents 2
Introduction 7
Hypertension Overview 8
Therapeutics Development 9
Hypertension - Therapeutics under Development by Companies 11
Hypertension - Therapeutics under Investigation by Universities/Institutes 19
Hypertension - Pipeline Products Glance 21
Hypertension - Products under Development by Companies 24
Hypertension - Products under Investigation by Universities/Institutes 37
Hypertension - Companies Involved in Therapeutics Development 39
Hypertension - Therapeutics Assessment 146
Drug Profiles 168
Hypertension - Dormant Projects 486
Hypertension - Discontinued Products 512
Hypertension - Product Development Milestones 515
Appendix 527
List of Tables
Number of Products under Development for Hypertension, H2 2016 32
Number of Products under Development for Hypertension - Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 34
Number of Products under Development by Companies, H2 2016 (Contd..1) 35
Number of Products under Development by Companies, H2 2016 (Contd..2) 36
Number of Products under Development by Companies, H2 2016 (Contd..3) 37
Number of Products under Development by Companies, H2 2016 (Contd..4) 38
Number of Products under Development by Companies, H2 2016 (Contd..5) 39
Number of Products under Development by Companies, H2 2016 (Contd..6) 40
Number of Products under Development by Companies, H2 2016 (Contd..7) 41
Number of Products under Investigation by Universities/Institutes, H2 2016 43
Comparative Analysis by Late Stage Development, H2 2016 44
Comparative Analysis by Clinical Stage Development, H2 2016 45
Comparative Analysis by Early Stage Development, H2 2016 46
Products under Development by Companies, H2 2016 47
Products under Development by Companies, H2 2016 (Contd..1) 48
Products under Development by Companies, H2 2016 (Contd..2) 49
Products under Development by Companies, H2 2016 (Contd..3) 50
Products under Development by Companies, H2 2016 (Contd..4) 51
Products under Development by Companies, H2 2016 (Contd..5) 52
Products under Development by Companies, H2 2016 (Contd..6) 53
Products under Development by Companies, H2 2016 (Contd..7) 54
Products under Development by Companies, H2 2016 (Contd..8) 55
Products under Development by Companies, H2 2016 (Contd..9) 56
Products under Development by Companies, H2 2016 (Contd..10) 57
Products under Development by Companies, H2 2016 (Contd..11) 58
Products under Development by Companies, H2 2016 (Contd..12) 59
Products under Investigation by Universities/Institutes, H2 2016 60
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 61
Hypertension - Pipeline by A1M Pharma AB, H2 2016 62
Hypertension - Pipeline by AbbVie Inc, H2 2016 63
Hypertension - Pipeline by Actelion Ltd, H2 2016 64
Hypertension - Pipeline by Afferent Pharmaceuticals Inc, H2 2016 65
Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 66
Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 67
Hypertension - Pipeline by AnGes MG Inc, H2 2016 68
Hypertension - Pipeline by APT Therapeutics Inc, H2 2016 69
Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2016 70
Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016 71
Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016 72
Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 73
Hypertension - Pipeline by Bayer AG, H2 2016 74
Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2016 75
Hypertension - Pipeline by Biolab Farmaceutica Ltda, H2 2016 76
Hypertension - Pipeline by BioRestorative Therapies Inc, H2 2016 77
Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 78
Hypertension - Pipeline by Cellceutix Corp, H2 2016 79
Hypertension - Pipeline by Celsion Corp, H2 2016 80
Hypertension - Pipeline by Celtaxsys Inc, H2 2016 81
Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 82
Hypertension - Pipeline by CJ HealthCare Corp, H2 2016 83
Hypertension - Pipeline by Complexa Inc, H2 2016 84
Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H2 2016 85
Hypertension - Pipeline by Corion Biotech Srl, H2 2016 86
Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H2 2016 87
Hypertension - Pipeline by Cytokinetics Inc, H2 2016 88
Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 89
Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 90
Hypertension - Pipeline by DiaMedica Inc, H2 2016 91
Hypertension - Pipeline by Eli Lilly and Company, H2 2016 92
Hypertension - Pipeline by Esperion Therapeutics Inc, H2 2016 93
Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 94
Hypertension - Pipeline by Ferring International Center SA, H2 2016 95
Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2016 96
Hypertension - Pipeline by Genextra Spa, H2 2016 97
Hypertension - Pipeline by Gilead Sciences Inc, H2 2016 98
Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2016 99
Hypertension - Pipeline by Glenveigh Medical LLC, H2 2016 100
Hypertension - Pipeline by HanAll Biopharma Co Ltd, H2 2016 101
Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 102
Hypertension - Pipeline by HitGen LTD, H2 2016 103
Hypertension - Pipeline by Innopharmax Inc, H2 2016 104
Hypertension - Pipeline by Insmed Inc, H2 2016 105
Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H2 2016 106
Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 107
Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 108
Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 109
Hypertension - Pipeline by Johnson & Johnson, H2 2016 110
Hypertension - Pipeline by JW Pharmaceutical Corp, H2 2016 111
Hypertension - Pipeline by Kowa Company Ltd, H2 2016 112
Hypertension - Pipeline by Leading BioSciences Inc, H2 2016 113
Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016 114
Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2016 115
Hypertension - Pipeline by LFB SA, H2 2016 116
Hypertension - Pipeline by LG Life Science LTD, H2 2016 117
Hypertension - Pipeline by LinXis BV, H2 2016 118
Hypertension - Pipeline by Liquidia Technologies Inc, H2 2016 119
Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 120
Hypertension - Pipeline by MannKind Corp, H2 2016 121
Hypertension - Pipeline by Mast Therapeutics Inc, H2 2016 122
Hypertension - Pipeline by Merck & Co Inc, H2 2016 123
Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2016 124
Hypertension - Pipeline by miRagen Therapeutics Inc, H2 2016 125
Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 126
Hypertension - Pipeline by Morphogen-IX Ltd, H2 2016 127
Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 128
Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2016 129
Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2016 130
Hypertension - Pipeline by Novartis AG, H2 2016 131
Hypertension - Pipeline by Noxamet Ltd, H2 2016 132
Hypertension - Pipeline by Omeros Corp, H2 2016 133
Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2016 134
Hypertension - Pipeline by Pfizer Inc, H2 2016 135
Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 136
Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2016 137
Hypertension - Pipeline by Polyphor Ltd, H2 2016 138
Hypertension - Pipeline by Proteo Inc, H2 2016 139
Hypertension - Pipeline by Pulmokine Inc, H2 2016 140
Hypertension - Pipeline by Quantum Genomics SA, H2 2016 141
Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2016 142
Hypertension - Pipeline by RedHill Biopharma Ltd, H2 2016 143
Hypertension - Pipeline by Respira Therapeutics Inc, H2 2016 144
Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2016 145
Hypertension - Pipeline by Sanofi, H2 2016 146
Hypertension - Pipeline by Selten Pharma Inc, H2 2016 147
Hypertension - Pipeline by Serodus ASA, H2 2016 148
Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 149
Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016 150
Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2016 151
Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2016 152
Hypertension - Pipeline by Suda Ltd, H2 2016 153
Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 154
Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 155
Hypertension - Pipeline by The Medicines Company, H2 2016 156
Hypertension - Pipeline by Theravance Biopharma Inc, H2 2016 157
Hypertension - Pipeline by Toray Industries Inc, H2 2016 158
Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 159
Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H2 2016 160
Hypertension - Pipeline by United Therapeutics Corp, H2 2016 161
Hypertension - Pipeline by VBS Pharmaceuticals, H2 2016 162
Hypertension - Pipeline by Vectura Group Plc, H2 2016 163
Hypertension - Pipeline by VG Life Sciences Inc, H2 2016 164
Hypertension - Pipeline by Vicore Pharma AB, H2 2016 165
Hypertension - Pipeline by XORTX Pharma Corp, H2 2016 166
Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 167
Hypertension - Pipeline by Yuhan Corp, H2 2016 168
Assessment by Monotherapy Products, H2 2016 169
Assessment by Combination Products, H2 2016 170
Number of Products by Stage and Target, H2 2016 172
Number of Products by Stage and Mechanism of Action, H2 2016 180
Number of Products by Stage and Route of Administration, H2 2016 188
Number of Products by Stage and Molecule Type, H2 2016 190
Hypertension - Dormant Projects, H2 2016 509
Hypertension - Dormant Projects (Contd..1), H2 2016 510
Hypertension - Dormant Projects (Contd..2), H2 2016 511
Hypertension - Dormant Projects (Contd..3), H2 2016 512
Hypertension - Dormant Projects (Contd..4), H2 2016 513
Hypertension - Dormant Projects (Contd..5), H2 2016 514
Hypertension - Dormant Projects (Contd..6), H2 2016 515
Hypertension - Dormant Projects (Contd..7), H2 2016 516
Hypertension - Dormant Projects (Contd..8), H2 2016 517
Hypertension - Dormant Projects (Contd..9), H2 2016 518
Hypertension - Dormant Projects (Contd..10), H2 2016 519
Hypertension - Dormant Projects (Contd..11), H2 2016 520
Hypertension - Dormant Projects (Contd..12), H2 2016 521
Hypertension - Dormant Projects (Contd..13), H2 2016 522
Hypertension - Dormant Projects (Contd..14), H2 2016 523
Hypertension - Dormant Projects (Contd..15), H2 2016 524
Hypertension - Dormant Projects (Contd..16), H2 2016 525
Hypertension - Dormant Projects (Contd..17), H2 2016 526
Hypertension - Dormant Projects (Contd..18), H2 2016 527
Hypertension - Dormant Projects (Contd..19), H2 2016 528
Hypertension - Dormant Projects (Contd..20), H2 2016 529
Hypertension - Dormant Projects (Contd..21), H2 2016 530
Hypertension - Dormant Projects (Contd..22), H2 2016 531
Hypertension - Dormant Projects (Contd..23), H2 2016 532
Hypertension - Dormant Projects (Contd..24), H2 2016 533
Hypertension - Dormant Projects (Contd..25), H2 2016 534
Hypertension - Discontinued Products, H2 2016 535
Hypertension - Discontinued Products (Contd..1), H2 2016 536
Hypertension - Discontinued Products (Contd..2), H2 2016 537
List of Figures
Number of Products under Development for Hypertension, H2 2016 32
Number of Products under Development for Hypertension - Comparative Analysis, H2 2016 33
Number of Products under Development by Companies, H2 2016 34
Number of Products under Investigation by Universities/Institutes, H2 2016 42
Comparative Analysis by Late Stage Development, H2 2016 44
Comparative Analysis by Clinical Stage Development, H2 2016 45
Comparative Analysis by Early Stage Products, H2 2016 46
Assessment by Monotherapy Products, H2 2016 169
Assessment by Combination Products, H2 2016 170
Number of Products by Top 10 Targets, H2 2016 171
Number of Products by Stage and Top 10 Targets, H2 2016 171
Number of Products by Top 10 Mechanism of Actions, H2 2016 179
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 179
Number of Products by Top 10 Routes of Administration, H2 2016 187
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 187
Number of Products by Top 10 Molecule Types, H2 2016 189
Number of Products by Stage and Top 10 Molecule Types, H2 2016 189
